GlassScriptPhysician profile
Ramanujan Samavedy
NPI 1922167790
$12,065.33
in general payments reported to CMS, 2019-2025
45 companies · $1,072 in 2025
The $1,072 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,445 · 2020: $911 · 2021: $1,052 · 2022: $730 · 2023: $975 · 2024: $880 · 2025: $1,072.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,927.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,927.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $7,192.81 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $620.43 | 2019-2025 | Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $582.43 | 2019-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $519.83 | 2019-2025 | Tremfya, Stelara, Remicade |
| Pfizer INC. | $346.84 | 2019-2025 | |
| Ferring Pharmaceuticals INC. | $245.91 | 2019-2025 | Rebyota |
| Merck Sharp & Dohme LLC | $208.22 | 2019-2024 | Dificid |
| Intercept Pharmaceuticals, INC. | $178.91 | 2019-2024 | Ocaliva |
| Aimmune Therapeutics, INC. | $174.16 | 2024-2025 | Zenpep |
| Regeneron Healthcare Solutions, INC. | $170.68 | 2019-2025 | Dupixent |
| Braintree Laboratories, INC. | $147.14 | 2019-2023 | Sutab, Suflave |
| Gilead Sciences, INC. | $139.11 | 2019-2025 | |
| Daiichi Sankyo INC. | $121.58 | 2019-2022 | |
| Celgene Corporation | $118.74 | 2022-2023 | Zeposia |
| Ardelyx, INC. | $112.69 | 2024-2025 | Ibsrela |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramanujan Samavedy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.